ABSTRACT
OBJECTIVE: Post-stroke paralysis is a common contributor to deep vein thrombosis (DVT) of the lower extremities, but little is known about its epidemiology and anatomy. This prospective study aimed to investigate the clinical incidence and anatomical distribution of lower-extremity DVT in acute stroke. PATIENTS AND METHODS: A total of 679 patients diagnosed with acute stroke (ischemic stroke, n = 507; hemorrhagic stroke, n = 172) were enrolled. Lower-extremity DVT was evaluated using vascular ultrasonography, and classified into three subtypes: central type, peripheral type and mixed type. Then, the incidence and anatomical distribution of DVT were analyzed. RESULTS: For patients with ischemic stroke, a total of 107 patients (21.1%) were affected by DVT, and 119 extremities were found with DVT, which included 114 extremities with peripheral-type DVT and five extremities with mixed-type DVT. For patients with hemorrhagic stroke, a total of 49 patients (28.5%) were affected by DVT, and 55 extremities were found with DVT, which included 51 extremities with peripheral-type DVT and four extremities with mixed-type DVT. The incidence of DVT was significantly higher in patients with hemorrhagic stroke than in patients with ischemic stroke (P < 0.05). Intermuscular veins were the most commonly affected (96.6%), followed by peroneal veins (15.5%), posterior tibial veins (9.2%), popliteal veins (4.0%), and femoral veins (4.0%). There was no significant difference in the anatomical distribution of DVT between ischemic and hemorrhagic stroke (P > 0.05). CONCLUSION: DVT is a common complication of acute stroke, and hemorrhagic stroke is associated with a higher incidence of DVT. The anatomical distribution of DVT revealed no heterogeneity between ischemic and hemorrhagic stroke, and isolated DVT in intermuscular veins were the most common.
Subject(s)
Brain Ischemia/epidemiology , Intracranial Hemorrhages/epidemiology , Lower Extremity/blood supply , Stroke/epidemiology , Ultrasonography , Venous Thrombosis/diagnostic imaging , Venous Thrombosis/etiology , Adult , Aged , Aged, 80 and over , Brain Ischemia/diagnostic imaging , China/epidemiology , Female , Humans , Incidence , Intracranial Hemorrhages/diagnostic imaging , Male , Middle Aged , Predictive Value of Tests , Prospective Studies , Risk Factors , Stroke/diagnostic imagingABSTRACT
BACKGROUND AND PURPOSE: Modified Thrombolysis in Cerebral Infarction (mTICI)2b/3 has been considered the criterion for successful reperfusion in endovascular treatment. This study aimed to compare the therapeutic safety and efficacy of mTICI2b and mTICI3 recanalization, and to analyze the factors related to outcomes in everyday clinical practice. MATERIALS AND METHODS: This is a single-center retrospective analysis of 224 patients who underwent successful thrombectomy (achieving a mTICI score ≥2b). The primary outcomes included a modified Rankin score (mRS) of 0-2 at 90-day, mortality, and symptomatic intracranial hemorrhage. RESULTS: A total of 111 patients achieved mTICI2b status (49.6%), and 113 achieved mTICI3 status (50.4%). The comparison between mTICI2b and 3 reperfusions showed no differences in short-term outcomes, 90-day mRS, complications, and mortality. There was a trend toward more passes in mTICI2b patients, although the difference was not significant. The univariate analysis showed that poor outcomes after endovascular treatment were associated with older age, previous history of coronary heart disease, atrial fibrillation, diabetes, tandem occlusions, high National Institutes of Health Stroke Scale (NIHSS) score on admission, and general anesthesia. A previous history of coronary heart disease, a high NIHSS score on admission, and the use of general anesthesia were independent factors that affected the therapeutic effects. CONCLUSION: The superiority (efficacy and safety) of mTICI3 reperfusion was not significant compared with that of mTICI2b reperfusion. Prolonged efforts to achieve mTICI3 after achieving mTICI2b should be considered prudently for those with difficulty achieving 100% reperfusion.
Subject(s)
Endovascular Procedures , Stroke/therapy , Thrombectomy , Aged , Cerebrovascular Circulation , China , Disability Evaluation , Endovascular Procedures/adverse effects , Endovascular Procedures/mortality , Female , Humans , Intracranial Hemorrhages/etiology , Male , Middle Aged , Recovery of Function , Retrospective Studies , Risk Factors , Stroke/diagnosis , Stroke/mortality , Stroke/physiopathology , Thrombectomy/adverse effects , Thrombectomy/mortality , Time Factors , Treatment OutcomeABSTRACT
Rationale/Aim: Intracranial atherosclerotic stenosis (ICAS) is a common cause of stroke in Asia and is significantly associated with stroke recurrence. The Balloon angiopLasty for intracranial Atherosclerotic minor Stroke/TIA (BLAST) study aims to evaluate the safety and effectiveness of early submaximal balloon angioplasty (SBA) combined with standard medical therapy vs. standard medical therapy alone in patients with minor stroke or transient ischemic attack (TIA) due to ICAS. Methods: The BLAST study is a multicenter prospective cohort study which will enroll patients with minor stroke or TIA due to symptomatic ICAS within 1 week of symptom onset from 20 centers in China. Eligible patients will receive either SBA with standard medical therapy or standard medical therapy alone based on the decision of the patient or legal representative. Participants will be followed up for 1 year. Study outcomes: The primary outcome is a composite of stroke or death within 30 days or ischemic stroke in the culprit artery territory from 30 days to 1 year. Secondary outcomes include stroke or death within 30 days, ischemic stroke in the culprit artery territory from 30 days to 1 year, restenosis rate of the culprit artery at 1 year, and neurological improvement at 90 days (assessed by mRS score). Safety outcomes include intracranial hemorrhage within 30 days and endovascular complications. Sample size estimate: According to previous studies, the incidence of the composite clinical outcomes is 15% in the group receiving medical therapy alone. We assumed the incidence would decrease to 5% in the SBA combined with the medical therapy group. The target sample size is 416 patients (208 per group), with 90% power and 5% type I error, allowing for a 10% loss to follow-up. Implications: The BLAST study will provide evidence regarding whether early SBA can reduce stroke recurrence and mortality in patients with minor stroke/TIA due to ICAS compared with medical therapy alone.Clinical trial registration:Clinicaltrials.gov, NCT06014723.
ABSTRACT
We describe a patient who underwent intracranial angioplasty and Solitaire stent placement for recanalization of a vertebrobasilar artery occlusion 2 months after symptom onset. Computed tomography angiography and digital subtraction angiography showed that both vertebral arteries and the proximal basilar artery were occluded. Balloon angioplasty was performed on a segment of the occluded left vertebral artery and basilar artery, followed by successful detachment of one Solitaire stent. Repeat angiography showed near normal patency of the left vertebrobasilar artery. The patient`s symptoms improved significantly, and postoperative transcranial Doppler sonography 3 months later showed no evidence of in-stent restenosis.
Subject(s)
Angioplasty/methods , Cerebral Revascularization/methods , Stents , Vertebrobasilar Insufficiency/therapy , Aged , Cerebral Angiography , Chronic Disease , Humans , Male , Treatment Outcome , Vertebrobasilar Insufficiency/diagnostic imagingABSTRACT
BACKGROUND: The potential benefit of intraarterial tenecteplase in acute basilar artery occlusion (BAO) patients with successful reperfusion following endovascular treatment (EVT) has not been studied. AIMS: To explore the efficacy and safety of intraarterial tenecteplase in acute BAO patients with successful reperfusion after EVT. SAMPLE SIZE ESTIMATES: A maximum of 228 patients are required to test the superiority hypothesis with 80% power according to a two-side 0.05 level of significance, stratified by center. DESIGN: We will conduct a prospective, randomized, adaptive-enrichment, open-label, blinded-end point, multicenter trial. Eligible BAO patients with successful recanalization after EVT [modified Thrombolysis in Cerebral Infarction (mTICI) 2b-3] will be randomly assigned into the experimental and control group with a 1:1 ratio. Patients in the experimental group will receive intraarterial tenecteplase (0.2-0.3 mg/min for 20-30 min), while patients in the control group will receive routine treatment according to the usual practice of each center. Patients in both groups will receive standard guideline-based medical treatment. OUTCOME: The primary efficacy endpoint is a favorable functional outcome, defined as the modified Rankin Scale 0-3 at 90 days after randomization. The primary safety endpoint is symptomatic intracerebral hemorrhage, defined as National Institutes of Health Stroke Scale score increase ⩾4 caused by intracranial hemorrhage within 48 h after randomization. Subgroup analysis of the primary outcome will be performed by age, gender, baseline NIHSS score, baseline pc-ASPECTS, intravenous thrombolysis, time from estimated symptom onset to treatment, mTICI, blood glucose, and stroke etiology. CONCLUSIONS: The results of this study will provide evidence of whether adjunct use of intraarterial tenecteplase after successful reperfusion with EVT is associated with better outcomes for acute BAO patients.
Subject(s)
Arterial Occlusive Diseases , Stroke , United States , Humans , Tenecteplase/therapeutic use , Basilar Artery/diagnostic imaging , Prospective Studies , Treatment Outcome , Stroke/diagnosis , Thrombectomy/methods , Cerebral InfarctionABSTRACT
Background: The best reperfusion strategy for medium-sized vessel occlusion (MeVO) is not well established. Given the proven treatment effect of intra-arterial thrombolysis in patients with large vessel occlusion (LVO), we hypothesized that intra-arterial tenecteplase (TNK) could increase the recanalization rate of MeVO and thus improve clinical outcome. Aims: To explore the safety and efficacy of intra-arterial TNK in patients with MeVO. Sample size estimates: A maximum of 80 patients are required to test the superiority hypothesis, using power = 80% and α = 0.025 to conduct the one-sided test. Design: Rescue treatment for mEdium veSsel oCclUsion by intra-artErial TNK (RESCUE-TNK) is a pilot, randomized, open-label, blinded end point, and multicenter trial. Eligible patients including primary MeVO as detected by the first DSA examination or secondary MeVO after endovascular treatment (EVT) for LVO will be assigned into the experimental group and control group as a ratio of 1:1. The experimental group will be treated with intra-arterial TNK (0.2-0.3 mg/min, for 20-30 min) via a microcatheter placed proximal to the site of occlusion, and the control group will be treated with routine therapy. Both groups of patients will be given standard stroke care based on the guidelines. Outcome: The primary efficacy end point is successful recanalization of MeVO, defined as the expanded treatment in cerebral ischemia (eTICI) score 2b67-3 after the procedure, while the primary safety end point is symptomatic intracranial hemorrhage (sICH), defined as National Institutes of Health Stroke Scale score increase ≥4 caused by intracranial hemorrhage within 24 (-6/+24) hours after randomization. Conclusion: The results of RESCUE-TNK will provide evidence for the efficacy and safety of intra-arterial TNK in the recanalization of patients with MeVO.
ABSTRACT
OBJECTIVE: To investigate factors associated with poor clinical outcomes in patients with acute ischemic stroke undergoing endovascular therapy. METHODS: A retrospective review of 265 patients with acute ischemic stroke treated in the First Hospital of Jilin University between January 1, 2016, and November 1, 2019, was performed. The primary outcome was the proportion of patients with a modified Rankin score of 0-2 at 90 days. Univariate and multivariate analyses were performed to assess potential clinical factors associated with a poor 90-day outcome. RESULTS: The rates of successful revascularization, good prognosis, symptomatic intracranial hemorrhage, and mortality were 84.5%, 46.0%, 9.8%, and 12.8%, respectively. As per univariate analysis, age, diagnosis of atrial fibrillation, diagnosis of diabetes, high baseline glucose level, tandem occlusion, high National Institutes of Health Stroke Scale (NIHSS) score at admission, general anesthesia, number of passes, high NIHSS score on discharge, unsuccessful recanalization (modified treatment in cerebral ischemia score <2b), and development of symptomatic intracranial hemorrhage, hemorrhagic infarction, parenchymal hematoma, and subarachnoid hemorrhage were associated with poor prognosis. Tobacco use was positive in correlation with good prognosis in univariate analysis. Diabetes, tandem occlusion, high NIHSS score at admission, and general anesthesia were independent factors associated with a poor 90-day outcome in multivariate analysis. CONCLUSIONS: Diabetes, tandem occlusion, high NIHSS score at admission, and general anesthesia were independent risk factors associated with a poor 90-day outcome and should be considered a reference by neurointerventionalists in guiding their clinical decision-making.
Subject(s)
Cerebrovascular Disorders/surgery , Endovascular Procedures/methods , Ischemic Stroke/surgery , Treatment Outcome , Adult , Aged , Cerebrovascular Disorders/complications , Female , Humans , Ischemic Stroke/etiology , Male , Middle Aged , Retrospective StudiesSubject(s)
Constriction, Pathologic/pathology , Constriction, Pathologic/surgery , Intracranial Hemorrhage, Hypertensive/etiology , Middle Cerebral Artery/surgery , Stents/adverse effects , Angiography, Digital Subtraction , Constriction, Pathologic/diagnostic imaging , Humans , Male , Middle Aged , Middle Cerebral Artery/diagnostic imaging , Tomography, X-Ray Computed , XenonABSTRACT
We reported 2 cases of vertebrobasilar junction artery dissection treated by different methods. Intra-artery thrombolysis was used to treat 1 patient, who died 53 hours after the procedure. The other case was treated by stenting for unaffected vertebral artery associated with a coil occlusion of affected vertebral artery, and the prognosis was good. These cases suggest that occlusion of proximal side of the vertebral artery affected by dissection and stenting for the junction between the other side of vertebral artery and the basilar artery may be a feasible method for vertebrobasilar junction artery dissection with or without thrombolysis.
Subject(s)
Brain Ischemia/therapy , Embolization, Therapeutic , Endovascular Procedures , Fibrinolytic Agents/administration & dosage , Stroke/therapy , Thrombolytic Therapy , Vertebral Artery Dissection/therapy , Vertebrobasilar Insufficiency/therapy , Angiography, Digital Subtraction , Brain Ischemia/etiology , Cerebral Angiography/methods , Endovascular Procedures/instrumentation , Fatal Outcome , Humans , Infusions, Intra-Arterial , Magnetic Resonance Imaging , Male , Middle Aged , Stents , Stroke/etiology , Treatment Outcome , Vertebral Artery Dissection/complications , Vertebrobasilar Insufficiency/etiologyABSTRACT
OBJECTIVE: To investigate the existence of an association between compensatory remodeling in symptomatic middle cerebral artery atherosclerotic stenosis with high-resolution magnetic resonance imaging (HR MRI) and transcranial color Doppler monitoring of microembolic signals (MESs). METHODS: A total of 36 consecutive patients with symptomatic middle cerebral artery atherosclerotic stenosis underwent MES monitoring by transcranial color Doppler and 3-T HR MRI. Proton density-weighted cross-sectional images with submillimeter voxel size were obtained. The remodeling patterns and plaque morphology of the sites of maximal luminal narrowing were analyzed in terms of their association with the MES data. RESULTS: Positive remodeling (PR) was found in 16 lesions (44·4%). The remodeling index was 1·11±0·05 in the PR group and 0·99±0·05 in the non-PR group (P<0·0001). Compared with the non-PR group, the PR group had a greater vessel area (19·97±1·42 mm(2) versus 18·23±1·23 mm(2)) and greater wall area (16·93±1·47 mm(2) versus 14·93±1·52 mm(2); both P<0·0001) at the sites of maximal luminal narrowing. Finally, MESs were observed more frequently in the PR group than in the non-PR group (62·5% versus 15·0%, P = 0·003). CONCLUSIONS: In patients with symptomatic middle cerebral artery atherosclerotic stenosis, MESs were observed more frequently in the PR group than in the non-PR group.